Stock MDP MEDEXUS PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medexus Pharmaceuticals Inc.

Equities

MDP

CA58410Q2036

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:58:13 2024-04-30 pm EDT 		5-day change 1st Jan Change
1.82 CAD -3.70% Intraday chart for Medexus Pharmaceuticals Inc. +10.30% -26.32%
Mar. 26 Medexus Pharmaceuticals Announces US Food and Drug Administration Approves It's Supplemental Biologics License Application for IXINITY(R) CI
Feb. 09 Medexus Pharmaceuticals Maintained at Speculative Buy at Stifel GMP After Fiscal Q3 Miss; Price Target Cut to C$2.85 MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 65.18 34.8 151.4 62.65 32.29 44.51 - -
Enterprise Value (EV) 1 65.18 67.96 183.2 62.65 32.29 44.51 44.51 44.51
P/E ratio -6.7 x -5.81 x -3.49 x -16.2 x 20.2 x -25.5 x 12 x 9.86 x
Yield - - - - - - - -
Capitalization / Revenue 1.92 x 0.47 x 1.56 x 0.63 x 0.23 x 0.29 x 0.29 x 0.27 x
EV / Revenue 1.92 x 0.47 x 1.56 x 0.63 x 0.23 x 0.29 x 0.29 x 0.27 x
EV / EBITDA 27.1 x 5.8 x 15.2 x -12.3 x 1.52 x 1.75 x 1.65 x 1.2 x
EV / FCF -20.6 x - 25.3 x - -16.3 x 1.54 x -4.93 x -5.01 x
FCF Yield -4.85% - 3.96% - -6.14% 65.1% -20.3% -20%
Price to Book 1.75 x 1.05 x - 2.65 x 1.08 x 1.01 x 0.87 x 0.63 x
Nbr of stocks (in thousands) 14,746 13,919 19,164 19,953 20,181 24,459 - -
Reference price 2 4.420 2.500 7.900 3.140 1.600 1.820 1.820 1.820
Announcement Date 7/8/19 6/22/20 6/16/21 6/22/22 6/21/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33.86 74.36 97.03 99.21 142.5 154.3 154.5 166.9
EBITDA 1 2.407 6 9.983 -5.085 21.29 25.49 27.05 37.12
EBIT 1 -5.865 -9.161 -1.675 -19.4 10.04 16.75 18.95 24.19
Operating Margin -17.32% -12.32% -1.73% -19.56% 7.04% 10.85% 12.27% 14.49%
Earnings before Tax (EBT) 1 -6.3 -7.357 -38.35 -4.941 -6.646 -1.805 3.114 9.231
Net income 1 -6.522 -6.236 -34.45 -3.724 1.61 -1.887 1.453 5.983
Net margin -19.26% -8.39% -35.51% -3.75% 1.13% -1.22% 0.94% 3.58%
EPS 2 -0.6600 -0.4300 -2.264 -0.1940 0.0791 -0.0715 0.1520 0.1845
Free Cash Flow 1 -3.163 - 5.99 - -1.984 28.96 -9.025 -8.891
FCF margin -9.34% - 6.17% - -1.39% 18.77% -5.84% -5.33%
FCF Conversion (EBITDA) - - 60% - - 113.62% - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 7/8/19 6/22/20 6/16/21 6/22/22 6/21/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 22.27 26.99 26.26 29.54 37.13 38.61 37.75 42.43 41.84 33.95 36.31 36.97 39.16 40.58 38.78
EBITDA 1 -2.508 2.408 1.398 2.448 5.628 7.019 6.359 9.213 7.347 4.346 5.74 6.193 7.706 8.257 5.78
EBIT 1 -6.208 -0.3802 -3.234 0.0424 2.611 3.897 3.605 6.508 4.904 2.112 3.314 2.964 3.098 3.368 3.502
Operating Margin -27.88% -1.41% -12.32% 0.14% 7.03% 10.09% 9.55% 15.34% 11.72% 6.22% 9.13% 8.02% 7.91% 8.3% 9.03%
Earnings before Tax (EBT) 1 9.478 -1.576 -4.668 -1.993 -3.407 -1.29 0.0158 1.189 -1.343 -1.071 -0.5989 -2.425 -2.29 -2.021 -1.886
Net income 1 12.62 -1.521 -6.839 -1.795 -3.661 -2.025 9.039 0.8754 -1.508 -0.7191 -0.551 -2.29 -2.155 -1.886 -1.751
Net margin 56.67% -5.63% -26.04% -6.08% -9.86% -5.25% 23.94% 2.06% -3.6% -2.12% -1.52% -6.19% -5.5% -4.65% -4.52%
EPS 2 0.6468 -0.0887 -0.3363 -0.0899 -0.1877 -0.0941 0.4483 0.0403 -0.0690 -0.0269 -0.0227 -0.1210 -0.1080 -0.0940 -0.0940
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 2/9/22 6/22/22 8/8/22 11/8/22 2/8/23 6/21/23 8/9/23 11/8/23 2/7/24 - - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - 33.2 31.9 - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - 5.526 x 3.191 x - - - - -
Free Cash Flow 1 -3.16 - 5.99 - -1.98 29 -9.03 -8.89
ROE (net income / shareholders' equity) -17.5% -17.4% - -16.1% 6.07% -3% 21% 28%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 2.520 2.380 - 1.180 1.480 1.810 2.090 2.890
Cash Flow per Share 2 -0.2600 -0.2400 - -0.0800 -0.0900 - - -0.6300
Capex 1 0.04 0.1 0.14 0.13 0.08 0.07 - -
Capex / Sales 0.13% 0.14% 0.15% 0.13% 0.06% 0.04% - -
Announcement Date 7/8/19 6/22/20 6/16/21 6/22/22 6/21/23 - - -
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Medexus Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.82 CAD
Average target price
3.208 CAD
Spread / Average Target
+76.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MEDEXUS PHARMACEUTICALS INC. Stock Medexus Pharmaceuticals Inc.
-26.32% 32.39M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MDP Stock
  4. Financials Medexus Pharmaceuticals Inc.